PATENT CLAIM ANALYSIS

Application Number: 16144198
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["514", "263100"]

Abstract:
The disclosure provides methods for treating cancer, including but not limited to, hematopoietic and lung cancers, using the HSP90 inhibitor, MPC-0767, as monotherapy and in combination therapy with additional active agents, including but not limited to, inhibitors of Bcl-2, EZH2 inhibitors, Ras/Raf/MEK/ERK pathway inhibitors, checkpoint inhibitors, DNMT inhibitors, ATO and chemotherapeutic agents. The disclosure also provides related compositions and methods of use.

Claim (Index 24):
The method of  claim 22 , wherein the Bcl-2 pathway inhibitor is selected from ABT-737, navitoclax, and venetoclax.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 97.0
- Lexical Diversity: 1.65217
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15419642', '15514043', '14671613', '14026778', '14447139']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.798655451837196
- 35 USC 102 Novelty (BERT): 0.526631766590097
- Combined Prediction Score: 0.7714530833124861
- Mean Citation Score: 313.314552
- Max Citation Score: 320.49805
- Similarity Product: 189.15942228552697

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test